Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unfavorable efficacy of pembrolizumab for advanced extramammary Paget's disease with high tumor mutation burden after failure of taxane-based regimens.

The Journal of dermatology - 1 Jun 2024

Koizumi Shigeru, Doi Reiichi, Aitake Urara, Lei Xiaofeng, Izumi Teruaki, Mori Tatsuhiko, Shojiguchi Naoko, Kawasaki Tomonori, Inozume Takashi, Kishi Akiko

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Mutation

Share to Skin Neoplasms

Share to Taxoids

Share to Treatment Failure

Source

Identifiers

PMID: 38216840
DOI: 10.1111/1346-8138.17101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unfavorable efficacy of pembrolizumab for advanced extramammary Paget's disease with high tumor mutation burden after failure of taxane-based regimens.PMID 38216840Read ↗

Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.Semantic proximity Read ↗

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinomaSemantic proximity Read ↗

Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.Semantic proximity Read ↗

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.Semantic proximity Read ↗

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).Semantic proximity Read ↗

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity Read ↗

Association of genetic alterations with prognosis in extramammary Paget disease: insights into the involvement of somatic CDKN2A variants in patients with a poor prognosis.Semantic proximity Read ↗

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.Semantic proximity Read ↗

Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.Semantic proximity Read ↗

Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumabSemantic proximity Read ↗

Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case reportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.